WHO Drug Information Vol. 13, No. 4, 1999
(1999; 83 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoGeneral Policy Issues
Abrir esta carpeta y ver su contenidoReports on Individual Drugs
Abrir esta carpeta y ver su contenidoCurrent Topics
Abrir esta carpeta y ver su contenidoVaccines and Biomedicines
Cerrar esta carpetaRegulatory and Safety Matters
Ver el documentoLeflunomide: pancytopenia and skin reactions
Ver el documentoDidanosine and pancreatitis
Ver el documentoSertraline for post-traumatic stress disorder
Ver el documentoPemoline withdrawal following liver complications
Ver el documentoLevetiracetam: new drug for epilepsy
Ver el documentoMethotrexate: monitoring essential
Ver el documentoMethotrexate: care in prescribing
Ver el documentoGrepafloxacin withdrawal: severe cardiovascular events
Ver el documentoReteplase incompatible with heparin
Ver el documentoPostmarketing system to be revised
Ver el documentoAbacavir: hypersensitivity reactions
Ver el documentoInitiative to curb illegal sale of drugs over the Internet
Ver el documentoUnapproved HIV test kits available on the Internet
Ver el documentoV-King®: unapproved use of sildenafil
Ver el documentoMiralex®: undeclared corticosteroid
Ver el documentoRules for dietary supplements finalized
Abrir esta carpeta y ver su contenidoATC/DDD Classification
Abrir esta carpeta y ver su contenidoEssential Drugs
Ver el documentoInternational Nonproprietary Names for Pharmaceutical Substances (INN)
Ver el documentoSelected WHO Publications of Related Interest
 

Initiative to curb illegal sale of drugs over the Internet

United States of America — A new initiative to protect consumers from the illegal sale of pharmaceuticals over the Internet has been proposed by the President of the USA. The initiative will include new Federal requirements for all Internet pharmacies to ensure that they comply with state and federal laws. It strengthens the current penalty structure for illegal pharmaceutical sales over the Internet by proposing a new civil penalty of US$ 500 000 for each violation of the sale of a prescription drug to an individual without a valid prescription. Two other major components strengthen the investigative processes and administrative subpoena authority of the Food and Drug Administration.

A new public education campaign on the potential dangers of buying prescription drugs on-line will be launched. In the opinion of the initiative, fly-by-night pharmacies put on-line consumers at increased risk for adverse reactions, dangerous drug interactions or contaminated drugs. The proposal will enable consumers to identify legitimate Internet pharmacy sites. In turn, sites will have to demonstrate their compliance with Federal and State law before they receive approval from the Food and Drug Administration to operate.

Reference: The White House, Office of the Press Secretary, 28 December 1999.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013